# Veeva Systems Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Veeva Systems Inc). ## Overview Veeva Systems is a U.S.-based software company focused on cloud applications, data products, and consulting services for the global life sciences industry. Its software supports pharmaceutical and biotechnology customers across research and development, quality, medical, and commercial operations, with offerings delivered primarily through the Veeva Vault platform and related cloud services. ## Products & services • Veeva Vault CRM and legacy Veeva CRM • Veeva Development Cloud applications • Veeva Quality Cloud applications • Veeva Commercial Cloud applications • Veeva Data Cloud and Veeva OpenData • Veeva Crossix analytics • Professional services and business consulting - **Commercial Cloud** (42%) — CRM, content, analytics, and engagement tools for life sciences commercial teams. - **R&D Solutions** (41%) — Development and quality applications used across clinical, regulatory, and quality workflows. - **Data Cloud** (10%) — Reference, deep, and transaction data products used to support commercial and clinical operations. - **Professional Services and Other** (7%) — Implementation, configuration, training, managed services, and consulting. - Veeva Vault CRM and legacy Veeva CRM - Veeva Development Cloud applications - Veeva Quality Cloud applications - Veeva Commercial Cloud applications - Veeva Data Cloud and Veeva OpenData - Veeva Crossix analytics - Professional services and business consulting ## Customers Veeva sells primarily to pharmaceutical and biotechnology companies that need specialized software for regulated workflows across the drug lifecycle. It also serves clinical research sites and, to a smaller extent, companies outside life sciences that use its development and quality applications. Customers buy Veeva to standardize processes, manage regulated content and data, and support commercial and R&D operations on a life-sciences-specific platform. - **Commercial Solutions customers** (primary) — Pharma and biotech companies buying CRM, medical, content, and analytics tools for commercialization and field engagement. - **R&D Solutions customers** (primary) — Life sciences companies using development and quality applications for clinical, regulatory, and quality workflows. - **Pre-commercial biotech and smaller R&D companies** (secondary) — Earlier-stage customers adopting Veeva for development workflows before commercialization. - **Clinical research sites** (secondary) — Sites using Veeva solutions that support clinical operations and related collaboration. - **Non-life-science enterprise customers** (emerging) — Selected customers outside life sciences using development and quality applications for regulated processes. - Pharmaceutical companies buying CRM, content, and data tools - Biotechnology firms using development and quality applications - Pre-commercial R&D customers adopting early-stage workflow software - Clinical research sites using life-sciences workflow applications - Non-life-science customers using selected development/quality tools ## Geography Veeva serves a global customer base, with subscription revenue concentrated in North America, Europe, and Asia Pacific. In the reported quarters, subscription services revenue was about 59-61% from North America, 27-28% from Europe, and 12-13% from other locations, primarily Asia Pacific. The geographic mix matters because the company’s life sciences customers operate globally, but demand and regulatory requirements vary by region. - **North America** (60%) — Approximate mix from reported subscription services revenue for recent quarters. - **Europe** (28%) — Approximate mix from reported subscription services revenue for recent quarters. - **Asia Pacific and Other** (12%) — Approximate mix from reported subscription services revenue for recent quarters. - North America is the largest subscription revenue region at about 59-61% - Europe contributes about 27-28% of subscription revenue - Asia Pacific and other regions contribute about 12-13% - Global life sciences customers require multi-region compliance support - Regional mix affects product localization and regulatory adaptation ## Strategy Veeva’s strategy centers on expanding its industry cloud footprint across the life sciences value chain, from R&D through commercialization. It emphasizes deepening customer adoption of its Vault platform, migrating customers to newer products such as Vault CRM, and extending its data and analytics offerings to increase workflow coverage and switching costs. - **Broaden the Vault platform footprint** (medium-term) — A unified platform increases customer stickiness and supports cross-sell across functions. - **Expand data and analytics offerings** (medium-term) — Data products deepen workflow integration and create recurring usage across commercial and clinical operations. - **Support customer migration to next-generation products** (short-term) — Migration from legacy systems helps preserve accounts and modernize the installed base. - **Extend consulting and implementation support** (short-term) — Services help customers deploy complex regulated workflows and reinforce platform adoption. - Expand adoption across R&D, quality, medical, and commercial workflows - Migrate customers from legacy CRM to Vault CRM on Veeva Vault - Grow data products such as OpenData, Link, Compass, and CRM Pulse - Increase customer use of existing products through broader module adoption - Use consulting and services to support implementation and workflow change ## Risks Veeva faces competition from large enterprise software vendors, life-sciences software specialists, and data/analytics providers, especially where customers can substitute broader platforms or legacy systems. Its business is also exposed to cybersecurity, privacy, product reliability, and regulatory-compliance risks because its software handles sensitive clinical, medical, and commercial data in highly regulated markets. - **Competitive pressure from enterprise and life-sciences software vendors** [high] — Customers can choose broader platforms or point solutions instead of Veeva modules. - **Migration risk from legacy CRM to Vault CRM** [high] — Transitioning customers to a new platform can create implementation friction and churn risk. - **Cybersecurity and data privacy breaches** [critical] — The company stores and processes sensitive customer and healthcare-related data. - **Regulatory and AI compliance risk** [high] — Life sciences software must adapt to evolving privacy, data, and AI rules across regions. - **Product defects or service disruptions** [high] — Failures in regulated workflows can reduce demand and create liability exposure. - Competition from Oracle, Salesforce, IQVIA, and other software vendors - Customer migration to Vault CRM can disrupt deployments and retention - Cybersecurity or privacy failures could damage trust and trigger liabilities - Product defects or outages could reduce demand and create support costs - AI-related compliance and reputational risks may slow adoption ## Accounting Veeva’s largest accounting judgment is revenue recognition, especially when contracts bundle multiple performance obligations across software, data, and services. Subscription revenue is recurring and seasonal, with the first fiscal quarter typically strongest for cash collections, while professional services and consulting require careful allocation and timing judgments. Standalone selling prices, customer type, and geography can affect how revenue is recognized across contract components. - **Revenue recognition and standalone selling price** — Can shift revenue timing between subscription, data, and services - **Seasonality of subscription billings** — Quarterly cash flow and working capital can be uneven - **Professional services and consulting revenue** — Affects mix, margin profile, and quarterly revenue cadence - **Stock-based compensation and RSU tax settlements** — Can create volatility in cash flow presentation - Revenue allocation across software, data, and services contracts - Standalone selling price estimates affect timing of revenue recognition - Seasonality in annual subscription billings affects quarterly comparability - Professional services and consulting revenue may be recognized differently - Stock-based compensation and RSU tax settlements affect financing cash flow --- *Last updated: 2026-08-11T04:03:56.228997+00:00*